Sensus Healthcare, Inc. reports developments tied to its medical-device business for superficial radiotherapy treatments for oncological and non-oncological skin conditions. The company’s updates center on SRT and IG-SRT technology, including systems used in the treatment of non-melanoma skin cancer and keloids, as well as products and services that support dermatology and radiation-oncology practices.
Recurring news topics include quarterly results, reimbursement and CPT coding for superficial radiotherapy, customer acquisition programs, financing options through Sensus Healthcare Financial Services, installed-base software such as Sensus Link, Fair Deal Agreement activity, international customer development, and commercial or legal matters related to product sales and deployments.
Sensus Healthcare (SRTS) reported Q1 2020 revenues of $1.7 million, down from $5.4 million in Q1 2019, attributed to COVID-19 impacts. The net loss widened to $3.6 million ($0.22 per share) from a loss of $2.1 million ($0.13 per share) a year prior. The company's installed base of SRT systems increased to 474, with four units shipped. Cash reserves rose slightly to $15.8 million. Management emphasized efforts to support customers during the pandemic and anticipates a potential increase in SRT adoption as reimbursement rates are expected to change in 2021.